


corresponding quinoline derivs. V (X = N) by successive oxidation
with m-ClC6H4CO2OH to give V (X = NO) treatment with ag. KOH and MeOH,
and methylation with MeI.



TECH CENTER 1600/2900

JUL 03 2002

RECEIVED

=> s jpl0029933/pn
L7 1 JP10029933/PN

=> d bib abs

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1998:76213 CAPLUS
DN 128:145388
TI Melatonin patches with good bioavailability
IN Hidaka, Osafumi; Kato, Toshiyuki
PA Teisan Seiyaku K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--10029933	A2	19980203	1996JP-0187551	19960717 <--
AB	The title patches comprise flexible water-(semi)permeable substrate films and compns. containing 0.05-0.4 part (based on total weight of the adhesive compns.) melatonin and vinyl acetate (I)-alkyl (meth)acrylate copolymers (I content ≥ 30 weight%) as adhesives. A patch containing 2.5:27.5:70 (by weight) acrylic acid-2-ethylhexyl acrylate-I copolymer 6, melatonin 2, and α -tocopherol 2 weight parts showed good bioavailability in rats.				

=> s jpl0029934/pn
L8 1 JP10029934/PN

=> d bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1998:76214 CAPLUS
DN 128:145389
TI Melatonin patches with good bioavailability
IN Hidaka, Yoshifumi; Kato, Toshiyuki
PA Teisan Seiyaku K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--10029934	A2	19980203	1996JP-0187552	19960717 <--
AB	The title patches comprise flexible water-(semi)permeable substrate films and compns. containing 0.04-0.2 part (based on total weight of the adhesive compns.) melatonin, 0.05-0.4 part α -tocopherol, its derivs., $C_{\geq 12}$ fatty acids, and/or their esters as additives, and adhesive copolymers of ≥ 50 mol% alkyl (average number of C ≥ 4) (meth)acrylates. A patch containing 3:90:7 (by weight) acrylic acid-2-ethylhexyl acrylate-methacrylic acid copolymer 7, melatonin 1, and α -tocopherol				

2 weight parts showed good bioavailability in rats.

=> s jp09136835/pn
L9 1 JP09136835/PN

=> d bib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1997:433181 CAPLUS
DN 127:55927
TI Flurazepam patches with good bioavailability
IN Hashimoto, Michiari; Yoneto, Kunio
PA Sekisui Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	<u>JP--09136835</u>	A2	19970527	1995JP-0295307	19951114 <--
AB	The title patches comprise a support and an overcoating adhesive layer containing (A) pressure-sensitive adhesive copolymers of 50-80 mol% C2-18 alkyl (meth)acrylates and 20-50 mol% vinylpyrrolidone (I), (B) flurazepam 1-20, (C) iso-Pr myristate (II) 10-40, (D) lauric acid diethanolamide (III) 1-15, and (E) SiO2 as irritation-reducing agents 5-20 weight% (based on the total adhesive layer). A patch containing 2-ethylhexyl acrylate-1,6-hexamethylene glycol dimethacrylate-I copolymer 90.0, flurazepam 10.0, II 30.0, III 10.0, and Aerosil 200 (SiO2) 17.0 parts (by weight) was applied to isolated murine skin to show flurazepam permeation 262 µg/cm2.				

=> s jp09143066/pn
L10 1 JP09143066/PN


=> d bib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1997:473576 CAPLUS
DN 127:86111
TI Diclofenac transdermal preparations
IN Nishida, Naoko; Yoneto, Kunio; Hashimoto, Michiari; Nekama, Tsutomu
PA Sekisui Chemical Co., Ltd., Japan; S. S. Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	<u>JP--09143066</u>	A2	19970603	1995JP-0329596	19951124 <--
AB	A transdermal preparation comprises (1) an adhesive containing copolymers of (meth)acrylic acid ester and vinylpyrrolidone, (2) diclofenac and/or its salts, (3) iso-Pr myristate, (4) lauric acid diethanolamide, and (5) silica as skin irritation-reducing agent. A mixture containing 2-ethylhexyl acrylate-N-vinyl-2-pyrrolidone-dimethacrylic acid-1,6-hexamethylene glycol				



TECH CENTER 1600/2900

JUL 03 2002

RECEIVED

copolymer 55, diclofenac Na 10, Aerosil 200 10, iso-Pr myristate 20,

lauric acid diethanolamide 5 % was added to EtOAc to give a homogeneous liquid, which was applied to a silicone-treated PET film and oven-dried.

The film was laminated with EVA film to give a transdermal preparation Tests for drug skin penetration and irritation were performed with hairless mouse skin samples.

=> s jp05132416/pn
L11 1 JP05132416/PN

=> d bib abs

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1993:154560 CAPLUS
DN 118:154560
TI Sustained-release pharmaceutical preparations based on gastrointestinal mucosa-adherent matrixes or coatings
IN Akiyama, Yohko; Hirai, Shinichiro; Nagahara, Naoki
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP----514008	A1	19921119	1992EP-0303357	19920414
	EP----514008	B1	19970305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL,				
PT, SE	AT----149348	E	19970315	1992AT-0303357	19920414
	ES---2098447	T3	19970501	1992ES-0303357	19920414
	JP--05132416	A2	19930528	1992JP-0122681	19920415 <--
	JP2001354593	A2	20011225	2001JP-0141178	19920415
	JP2001354550	A2	20011225	2001JP-0141179	19920415
	CA---2066384	AA	19921020	1992CA-2066384	19920416
	US---5576025	A	19961119	1995US-0412591	19950329
	US---5731006	A	19980324	1996US-0697166	19960820
PRAI	1991JP-0116745	A	19910419		
	1991JP-0225155	A	19910809		
	1992JP-0122681	A3	19920415		
	1992US-0870637	B1	19920420		
	1994US-0200539	B1	19940222		
	1995US-0412591	A3	19950329		

OS MARPAT 118:154560
AB A solid matrix composition which is solid at ambient temperature comprises a viscogenic agent, e.g acrylic acid polymer, capable of developing viscosity on contact with water, as dispersed at least in the neighborhood of the surface layer of matrix particles containing a polyglycerol fatty acid ester or a lipid and an active ingredient. Thus, idebenone and Carbopol 934P (I) were added to melted stearyl penta(tetra)glyceride and stirred at 80° for 15 min to give a dispersion. The molten mixture was then dropped onto a rotating disk to obtain fine spherical granules of 30-80 mesh. The above granules and control granules having no I were orally administered to rats in a dose of 100 mg/kg and 3h later rats were